C-Abl tyrosine kinase promotes adipocyte differentiation by targeting PPAR-gamma 2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 46, 2014, Pages 16365-16370

  Keshet, Rom ^a   Kraitshtein, Zina Bryansker ^a   Shanzer, Matan ^a   Adler, Julia ^a   Reuven, Nina ^a   Shaul, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Adipogenesis; C Abl; Differentiation; PPAR gamma; Pro12Ala polymorphism

Indexed keywords

ABELSON KINASE; ACTIVATION FUNCTION 1; ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; PROTEIN; TYROSINE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; IMATINIB; ISOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOTYROSINE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADIPOCYTE; ADIPOGENESIS; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; NONHUMAN; PHENOTYPE; PROADIPOCYTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEOMICS; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MISSENSE MUTATION; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES DIFFERENCE;

MURINAE;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; BENZAMIDES; HEK293 CELLS; HUMANS; IMATINIB MESYLATE; MICE; MUTATION, MISSENSE; NIH 3T3 CELLS; PHOSPHORYLATION; PHOSPHOTYROSINE; PIPERAZINES; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROLINE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 84911944002     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411086111     Document Type: Article

References (44)

1. Rosen ED (2002) The molecular control of adipogenesis, with special reference to lymphatic pathology. Ann N Y Acad Sci 979:143-158, discussion 188-196.
2. Castillo G, et al. (1999) An adipogenic cofactor bound by the differentiation domain of PPARgamma. EMBO J 18(13):3676-3687.
3. Bugge A, Grontved L, Aagaard MM, Borup R, Mandrup S (2009) The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment. Mol Endocrinol 23(6):794-808.
4. Shao D, et al. (1998) Interdomain communication regulating ligand binding by PPARgamma. Nature 396(6709):377-380.
5. Chambon P (2005) The nuclear receptor superfamily: A personal retrospect on the first two decades. Mol Endocrinol 19(6):1418-1428.
6. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 8(10):1224-1234.
7. Ohshima T, Koga H, Shimotohno K (2004) Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 279(28):29551-29557.
8. Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274(5295):2100-2103.
9. Yen CJ, et al. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241(2):270-274.
10. Deeb SS, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284-287.
11. Heikkinen S, et al. (2009) The Pro12Ala PPARgamma2 variant determines metabolism at the gene-environment interface. Cell Metab 9(1):88-98.
12. Yuan ZM, et al. (1996) Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 382(6588):272-274.
13. Agami R, Blandino G, Oren M, Shaul Y (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399(6738):809-813.
14. Levy D, Adamovich Y, Reuven N, Shaul Y (2008) Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 29(3):350-361.
15. Bennett RL, Hoffmann FM (1992) Increased levels of the Drosophila Abelson tyrosine kinase in nerves and muscles: Subcellular localization and mutant phenotypes imply a role in cell-cell interactions. Development 116(4):953-966.
16. Daniel R, Wong PM, Chung SW (1996) Isoform-specific functions of c-abl: Type I is necessary for differentiation, and type IV is inhibitory to apoptosis. Cell Growth Differ 7(9):1141-1148.
17. Koch A, et al. (2000) Direct interaction of nerve growth factor receptor, TrkA, with non-receptor tyrosine kinase, c-Abl, through the activation loop. FEBS Lett 469(1):72-76.
18. Lee YC, et al. (2010) Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22):3196-3207.
19. O'Neill AJ, Cotter TG, Russell JM, Gaffney EF (1997) Abl expression in human fetal and adult tissues, tumours, and tumour microvessels. J Pathol 183(3):325-329.
20. Frasca F, et al. (2007) Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J Biol Chem 282(36):26077-26088.
21. Wilson B, Liotta LA, Petricoiniii E (2013) Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation. Mol Cell Proteomics 12(9):2522-2535.
22. Brasher BB, Van Etten RA (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275(45):35631-35637.
23. Buchdunger E, et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139-145.
24. Matsubara Y, Suzuki H, Ikeda Y, Murata M (2010) Generation of megakaryocytes and platelets from preadipocyte cell line 3T3-L1, but not the parent cell line 3T3, in vitro. Biochem Biophys Res Commun 402(4):796-800.
25. Vaziri C, Faller DV (1996) Down-regulation of platelet-derived growth factor receptor expression during terminal differentiation of 3T3-L1 pre-adipocyte fibroblasts. J Biol Chem 271(23):13642-13648.
26. Ren R, Mayer BJ, Cicchetti P, Baltimore D (1993) Identification of a ten-amino acid proline-rich SH3 binding site. Science 259(5098):1157-1161.
27. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS (2002) PPARgamma knockdown by engineered transcription factors: Exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16(1):27-32.
28. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79(7):1147-1156.
29. Zhang B, et al. (1992) Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA 89(16):7541-7545.
30. Puigserver P, et al. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92(6):829-839.
31. Tsai KK, Yuan ZM (2003) c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 63(12):3418-3424.
32. Shaul Y (2000) c-Abl: Activation and nuclear targets. Cell Death Differ 7(1):10-16.
33. Baskaran R, et al. (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387(6632):516-519.
34. Yang DQ, Kastan MB (2000) Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2(12):893-898.
35. Altanerova V, Horvathova E, Matuskova M, Kucerova L, Altaner C (2009) Genotoxic damage of human adipose-tissue derived mesenchymal stem cells triggers their terminal differentiation. Neoplasma 56(6):542-547.
36. Lee H, Lee YJ, Choi H, Ko EH, Kim JW (2009) Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J Biol Chem 284(16):10601-10609.
37. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl protooncogene. Cell 65(7):1153-1163.
38. Fitter S, et al. (2008) Long-term imatinib therapy promotes bone formation in CML patients. Blood 111(5):2538-2547.
39. Fitter S, et al. (2010) Plasma adiponectin levels are markedly elevated in imatinibtreated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95(8):3763-3767.
40. Fitter S, Vandyke K, Gronthos S, Zannettino AC (2012) Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol 48(3):229-240.
41. Kubota N, et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4(4):597-609.
42. Machuy N, Rajalingam K, Rudel T (2004) Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis. Cell Death Differ 11(3):290-300.
43. Yu D, et al. (2004) Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J Biol Chem 279(50):51851-51861.
44. Tontonoz P, Spiegelman BM (2008) Fat and beyond: The diverse biology of PPARgamma. Annu Rev Biochem 77:289-312.